TY - JOUR
AU - Chanda, Sanjay
AB - Tavaborole, a cyclized boronic acid, has been approved by the Food and Drug Administration for the topical treatment of toenail onychomycosis. This novel, low-molecular-weight pharmaceutical compound has broad-spectrum antifungal activity against dermatophytes, yeasts, and molds responsible for the disease. Tavaborole was tested in 2-year carcinogenicity studies in mice (once daily dermal administration) and rats (once daily by oral gavage) as part of the extensive nonclinical safety program. There was no evidence of tavaborole-related neoplasms observed in either study. Based on the data gathered from these 2 carcinogenicity studies, tavaborole is considered noncarcinogenic.
TI - Tavaborole, a Novel Boron-Containing Small Molecule for the Topical Treatment of Onychomycosis, Is Noncarcinogenic in 2-Year Carcinogenicity Studies
JF - International Journal of Toxicology
DO - 10.1177/1091581814545245
DA - 2014-09-01
UR - https://www.deepdyve.com/lp/sage/tavaborole-a-novel-boron-containing-small-molecule-for-the-topical-MQaT9vdsJG
SP - 419
EP - 427
VL - 33
IS - 5
DP - DeepDyve
ER -